Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME) - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Therapeutic Advances in Medical Oncology Année : 2020

Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME)

Junien Sirieix
  • Fonction : Auteur
Julien Fraisse
  • Fonction : Auteur
Simone Mathoulin-Pelissier
  • Fonction : Auteur
Marianne Leheurteur
  • Fonction : Auteur
Laurence Vanlemmens
Christelle Jouannaud
  • Fonction : Auteur
Véronique Diéras
  • Fonction : Auteur
Christelle Lévy
Mony Ung
  • Fonction : Auteur
Thierry Petit
Bruno Coudert
  • Fonction : Auteur
Etienne Brain
Barbara Pistilli
  • Fonction : Auteur
Jean-Marc Ferrero
Anthony Goncalves
Lionel Uwer
  • Fonction : Auteur
Anne Patsouris
  • Fonction : Auteur
Olivier Tredan
  • Fonction : Auteur
Coralie Courtinard
  • Fonction : Auteur
Sophie Gourgou
  • Fonction : Auteur
Jean-Sébastien Frénel

Résumé

Background and Aims: Because of its low prevalence, metastatic breast cancer (MBC) in males is managed based on clinical experience with women. Using a real-life database, we aim to provide a comprehensive analysis of male MBC characteristics, management and outcome. Methods: The Epidemiological Strategy and Medical Economics Data Platform collected data for all men and women ⩾18 years with MBC in 18 participating French Comprehensive Cancer Centers from January 2008 to November 2016. Demographic, clinical, and pathological characteristics were retrieved, as was treatment modality. Men were matched 1:1 to women with similar characteristics. Results: Of 16,701 evaluable patients, 149 (0.89%) men were identified. These men were older (median age 69 years) and predominantly had hormone receptor HR+/HER2– disease (78.3%). Median overall survival (OS) was 41.8 months [95% confidence interval (CI: 26.9–49.7)] and similar to women. Median progression-free survival (PFS) with first-line therapy was 9.3 months [95% CI (7.4–11.5)]. In the HR+/HER2– subpopulation, endocrine therapy (ET) alone was the frontline treatment for 43% of patients, including antiestrogens ( n = 19), aromatase inhibitors ( n = 15) with luteinizing hormone-releasing hormone (LHRH) analogs ( n = 3), and various sequential treatments. Median PFS achieved by frontline ET alone was similar in men [9.8 months, 95% CI (6.9–17.4)] and in women [13 months, 95% CI (8.4–30.9)] ( p = 0.80). PFS was similar for HR+/HER2– men receiving upfront ET or chemotherapy: 9.8 months [95% CI (6.9–17.4)] versus 9.5 months [95% CI (7.4–11.7)] ( p = 0.22), respectively. Conclusion: MBC management in men and women leads to similar outcomes, especially in HR+/HER2– patients for whom ET should also be a cornerstone. Unsolved questions remain and successfully recruiting trials for men are still lacking.

Dates et versions

hal-03426477 , version 1 (12-11-2021)

Identifiants

Citer

Junien Sirieix, Julien Fraisse, Simone Mathoulin-Pelissier, Marianne Leheurteur, Laurence Vanlemmens, et al.. Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME). Therapeutic Advances in Medical Oncology, 2020, 12, pp.175883592098054. ⟨10.1177/1758835920980548⟩. ⟨hal-03426477⟩
15 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More